TOP 10%

CRISPR

by Medsky Topics @topics.medsky.network

A Medsky Topics feed composed of posts covering recent news related to the gene-editing technology, CRISPR Powered by @medsky.network

Open and pin on Bluesky Share on Bluesky
13
Likes
+0
Growth per month

In the feed right now

Live from Bluesky
Max Planck Institute of Immunobiology and Epigenetics @mpi-ie.bsky.social · about 11 hours ago
Next week, we are super happy to welcome Prof Silvia Domcke (@sdomcke.bsky.social) from Zürich. In her talk, Silvia will show how large-scale, single-cell-resolved CRISPR screens can be used to uncover the complex roles of TFs in shaping cell fate and disease. 🗓️ Mon, 26 Oct 2026, 13:00
Seminar announcement with a portrait of a woman and text about a talk titled 'Perturbing cell fate regulators across biological contexts' by Silvia Domcke from University of Zürich, Switzerland, scheduled for Monday, 26 October 2026, 13:00 at MPI-IE, Stübeweg 51, Freiburg, hosted by Oliver Sinotas.
Replies0 Reposts1 Likes1
Rockefeller University Press @rupress.org · 2 days ago
In @jhumimmunity.org: Using CRISPR/Cas9, Webbers, Rojas-Rodriguez, Kuijpers et al. show that disruption of kindlin-3 in cultured #neutrophils largely recapitulates the LAD-III phenotype but some effector functions remain upon stimulation without intact kindlin-3. rupress.org/jhi/article/...
Replies0 Reposts0 Likes1
Science Magazine @science.org · 3 days ago
14 years ago, the revolutionary genetic tool CRISPR/Cas9 was published in Science, work that Emmanuelle Charpentier and Jennifer Doudna won a Nobel Prize for in 2020. On #WorldCRISPRDay, read the landmark paper that describes the discovery: scim.ag/4oot170
(Top) In type II CRISPR/Cas systems, Cas9 is guided by a two-RNA structure formed by activating tracrRNA and targeting crRNA to cleave site-specifically–targeted dsDNA (see fig. S1). (Bottom) A chimeric RNA generated by fusing the 3′ end of crRNA to the 5′ end of tracrRNA.
Replies0 Reposts18 Likes68
Dementia Researcher @dementiaresearcher.bsky.social · 5 days ago
The University of Hong Kong seeks a Postdoctoral Fellow to develop lipid nanoparticle-delivered CRISPR-Cas9 gene editing for ALS and frontotemporal dementia. Closing date: 31st January www.dementiaresearcher.ni….
Replies0 Reposts0 Likes0
NEJM.org @nejm.org · 5 days ago
In a phase 3, randomized trial of lonvo-z, an in vivo gene-editing therapy, patients with hereditary angioedema who received the drug had a significantly lower attack rate than those who received placebo. Full HAELO trial results and Research Summary: nej.md/4gaSsbi
This image contains an excerpt from the Research Summary "In Vivo CRISPR Gene Editing in Hereditary Angioedema” published in the New England Journal of Medicine. It shows a comparison between Lonvo-z and Placebo. An illustration depicts an individual experiencing swelling from hereditary angioedema. The study includes 80 adults with a median age of 42 (women: 69%; men: 31%). A prompt to read the full Research Summary at NEJM.org sits at the bottom.
Replies0 Reposts1 Likes6
Life Science Alliance @lsajournal.org · 20 days ago
New study: PZL-26 selectively inhibits mitochondrial protease LONP1, sparing the proteasome. CRISPR screening and proteomics reveal LONP1's roles in OXPHOS and mitochondrial gene expression. www.life-science-alliance….
Replies0 Reposts0 Likes1
Keep reading on Bluesky